🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesType 1.5 diabetes (LADA) and GLP-1 — May 2025 Page 2

Type 1.5 diabetes (LADA) and GLP-1 — May 2025

WendyG_ATL Sun, Mar 17, 2024 at 9:03 PM 12 replies 1,944 viewsPage 2 of 3
AttorneyGrant
Member
567
2,890
Apr 2024
Washington, DC
Mar 17, 2024 at 11:53 PM#6

Does anyone know if insurance continues to cover semaglutide once the diabetes diagnosis is removed? That's my concern — I'm in a similar trajectory and worried about losing coverage.

48 4Dr.SleepRoch, laura_annarbor, JenMemphis and 45 others
Reply Quote Save Share Report
mike.trainer_LA
Senior Member
1,567
7,234
Apr 2024
Los Angeles, CA
Mar 18, 2024 at 12:10 AM#7
Does anyone know if insurance continues to cover semaglutide once the diabetes diagnosis is removed?

This varies hugely by plan. Some will switch the indication to obesity management (BMI-based), some require a new prior auth, and some will drop coverage entirely. It's worth having a proactive conversation with your endo about coding strategy before the diagnosis is officially changed. Some docs will keep "insulin resistance" or "pre-diabetes" as a code even after A1C normalizes, which can preserve coverage.

17 2newstart_MO, mia_MS2, LeilaHI and 14 others
Reply Quote Save Share Report
kim_atl_prep
Member
312
1,345
Aug 2024
Atlanta, GA
Mar 18, 2024 at 12:27 AM#8

Good point about insurance. My endo is keeping me coded as "obesity, BMI 31.5" which is still accurate and is a covered indication on my plan. She was very thoughtful about the timing. The T2D history code is also documented which helps with prior auths.

Last edited: Mar 18, 2024 at 6:27 AM
43 23RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 40 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
quinn_sf
Member
489
2,123
Jun 2024
San Francisco, CA
Mar 18, 2024 at 12:44 AM#9

For those who like numbers, here's what the research says about this kind of trajectory:

The STEP 2 trial showed an average A1C reduction of 1.6 percentage points on semaglutide 2.4mg in patients with T2D. An A1C drop of 3.8 points (9.2 to 5.4) is well above average, which suggests diet/exercise modifications played a significant complementary role. The weight loss of 66 lbs (~25%) is also above the trial average of ~10%, further supporting that lifestyle changes amplified the pharmacological effect.

Great result. The data backs up the approach.

39 22andrew_nyc, Dr.EndoEP, GraceAZ_72 and 36 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register